Organigram Global (OGI) vs Tiziana Life Sciences (TLSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tiziana Life Sciences (TLSA) has outperformed Organigram Global (OGI) over the past year, losing 50.7% versus a loss of 51.0%. Over five years, TLSA leads with a -25.2% price change compared with -89.3% for OGI. Tiziana Life Sciences is the larger company by market cap ($143.8 million vs $137.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OGI | TLSA |
|---|---|---|
| Share price | $0.9511 | $1.13 |
| Market cap | $137.10M | $143.80M |
| 1-day change | -0.93% | +2.73% |
| YTD return | -43.39% | -24.16% |
| 1-year return | -50.97% | -50.66% |
| 5-year return | -89.29% | -25.17% |
| P/E ratio (TTM) | 2.21 | — |
| Forward P/E | 39.63 | — |
| EPS (TTM) | $0.43 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.24 | $2.25 |
| 52-week low | $0.853 | $0.76 |
| Distance from 52-week high | -57.54% | -49.78% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | — | +606.19% |
| Average volume | 884.72K | 720.16K |
| Shares outstanding | 144.15M | 127.26M |
| Employees | 1,139 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Organigram Global
OGI stock →Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,139 employees
About Tiziana Life Sciences
TLSA stock →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
OGI vs TLSA FAQ
Which is bigger, Organigram Global or Tiziana Life Sciences?
Tiziana Life Sciences (TLSA) is larger, with a market capitalization of $143.80M compared with $137.10M for Organigram Global (OGI).
Which stock has performed better over the past year, OGI or TLSA?
TLSA returned -50.66% over the past 12 months, compared with -50.97% for OGI (price return, excluding dividends). Past performance does not predict future results.
Are Organigram Global and Tiziana Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.